- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Neumora Therapeutics to Report Q4 2025 Earnings on Monday
The clinical-stage biopharmaceutical company focused on central nervous system disorders will release its latest quarterly results.
Mar. 3, 2026 at 2:07am
Got story updates? Submit your updates here. ›
Neumora Therapeutics (NASDAQ:NMRA) is scheduled to report its fourth quarter 2025 financial results before the market opens on Monday, March 2nd. Analysts expect the company to post a loss of $0.34 per share for the quarter. Neumora will host a conference call to discuss the earnings report on Tuesday, March 3rd at 4:30 PM ET.
Why it matters
As a clinical-stage biotech company, Neumora's quarterly earnings reports provide important updates on the progress of its pipeline of experimental treatments for neurological and psychiatric disorders. Investors will be closely watching the company's financial performance and any new developments with its drug candidates.
The details
Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is focused on developing precision therapies for central nervous system disorders. The company applies an integrated approach combining biological insights, single-cell genomics and machine learning to accelerate drug discovery and development.
- Neumora Therapeutics will report its Q4 2025 results before the market opens on Monday, March 2nd.
- The company will host a conference call to discuss the earnings report on Tuesday, March 3rd at 4:30 PM ET.
The players
Neumora Therapeutics
A clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system.
Paul L. Berns
An insider at Neumora Therapeutics who sold 9,819 shares of the company's stock in a transaction on February 17th.
The takeaway
Neumora Therapeutics' upcoming earnings report will provide investors with an update on the progress of the company's pipeline of experimental treatments for neurological and psychiatric disorders, which could have significant implications for the future of the business.
